receptor agonist U46619 induced platelet aggregation (up to 75%), dexamethasone had no effect.
Introduction
The glucocorticoid receptor (GR) is a member of the nuclear hormone receptor super-family that encompasses, among others, oestrogen receptor and peroxisome proliferators activated receptor.
Natural and synthetic glucocorticoids bind to GR producing major conformational changes that results in nuclear translocation or transrepression of transcription factors including nuclear factor kB 1, 2 . In all cases, the majority of the ensuing glucocorticoid actions are mediated by GR and culminate in a modification of the synthesis and expression of pivotal mediators of innate and adaptive immunity 3 .
Despite their extensive use in cardiovascular and immune pathologies, glucocorticoids have been reported to be largely inactive on platelet functions. Human studies in healthy volunteers have shown the lack of effect of dexamethasone (Dex) treatment in inhibiting renal excretion of the thromboxane A 2 stable metabolite, thromboxane B 2 (TxB 2 ) 4 . Similarly, conventional clinical doses of prednisone do not impair platelet function or enhance primary haemostatis in normal subjects as measured by the bleeding time 5 . Since changes in de novo protein synthesis are the basis for glucocorticoid effectiveness, the lack of a modulatory effect on platelet functions is not surprising given that these cells have been regarded as being incapable of synthetic activity.
More recently, though, platelets have been shown to produce and release several mediators by de novo synthesis from preformed mRNA 6 .
It has recently emerged that glucocorticoids can modulate cell functions via non-genomic processes 7, 8 . Thus, glucocorticoid interaction with GR can lead to rapid effects such as the direct -4 -inhibitory action on nuclear factor κB activation 9 . The ability of the ligand/GR complex to directly affect several distinct signal pathways has been reported in several studies, such that their actions may be considered two fold. On one hand it produces rapid changes in cell behaviour whilst, on the other, it modulates transcription factor activation with consequent alteration of protein synthesis without the necessity of nuclear localization, 10, 11 . Non-genomic glucocorticoid effects modulate the function of immune cells and are emerging as an important contributor to their overall control on cellular function 12 .
Until recently platelets were thought to be involved solely in the maintenance of vessel homeostasis and repair, possessing little other activity that could impact on the inflammatory process. However, these anuclear cells are comparable with other immune cells as rich sources of inflammatory mediators -recently reviewed in ref. 13 . Thus, platelets can rapidly release high levels of CXCL4, CXCL5 and CCL5 and contribute to neutrophil and monocyte recruitment.
Similarly, apart from the effect of anti-platelet therapy for thrombotic disorders, platelets -and drugs that affect them -may play a role in other types of vascular inflammation. As an example, recent studies have highlighted the role of platelets in leukocyte adhesion to activated postcapillary venule endothelium 14 as well as in other models of chronic inflammatory pathologies [15] [16] [17] .
In the present study we report the presence of functional GR in human platelets. Using an integrated approach based on a series of functional and biochemical analyses we provide evidence that platelet GR can interact with synthetic ligands in a fashion that is distinct from that reported for other blood cells. 
Materials and methods

Chemicals
Thromboxane B 2 (TxB 2 ), prostaglandin B 1 (PGB 1 ), acetylsalicylic acid (aspirin™ or ASA), citric acid and the thromboxane A 2 receptor agonist U46619 were purchased from Sigma-Aldrich (Poole, UK). 12-R-Hydroxyeicosatetraenoic acid (12-R-HETE), arachidonic acid (AA) and 12-S-Hydroxyheptadecatrienoic acid (12-S-HHTrE) were purchased from Cayman Chemical (Ann Arbor, MI, USA). Acetonitrile (HPLC grade), methanol (HPLC grade), pyridine (AR) and acetic anhydride (AR) were from VWR (Lutterworth, UK). 9-anthryl diazomethane (ADAM) was obtained from Molecular Probes (Leiden, Netherlands). Water was purified with a Millipore Milli-Q water purification system (Millipore, Watford, UK).
The glucocorticoids, dexamethasone, prednisolone, hydrocortisone and aldosterone were obtained from SigmaAldrich, whilst NCX-1015 (prednisolone 21-[4'-(nitrooxymethyl)benzoate) was a generous gift of Dr E Ongini (NicOx SA, Milan, Italy).
Platelet preparations
Experiments with healthy volunteers were approved by the local Research Ethics Committee (P/00/029 ELCHA). Venous blood (40 ml) was taken from consenting healthy male volunteers was taken and transferred immediately to citrated tubes. Samples were centrifuged for 10 min at 2000 rpm at 25°C. Using a Pasteur pipette, platelet-rich plasma (PRP) was carefully removed to separate polypropylene tubes and retained at room temperature until required (usually less than 1h). Platelet-poor plasma (PPP) was prepared from PRP by centrifugation at 2000 rpm for 5 min at room temperature. For the washed platelet preparation, prostacyclin (300 ng/ml) was added to GR using a specific rabbit polyclonal antibody (PA-512, Affinity Bioreagents, Golden, CO) and for P-selectin CD62P with a mouse monoclonal antibody (Serotec, Oxford, UK) using a previously described protocol for intracellular fluorescence staining using propidium iodide as a nuclear counterstain 18 . Stained cells were observed under oil immersion objective lens by confocal microscopy (with a Leica confocal microscope, equipped with a 488-and 514-nm dual band argon laser) and images collected using TCSNT software (Leica, Solms, Germany). PRP aggregation assay PRP (500 µl aliquot) was added to Payton aggregation module (dual channel) and the instrument
For personal use only. by on April 14, 2008. www.bloodjournal.org From calibrated as specified by the manufacturer, normalising maximum transmittance on the PPP value recorded from a cuvette without stirring. Following a 3 min stabilization period at 37°C, either vehicle or glucocorticoids were added in a 10 µl volume followed after 5 min by ADP (4 µM). This concentration was chosen following an examination of the dose response curve in preliminary experiments and gave ~80% of the maximal response (not shown). In selected experiments, two glucocorticoids (e.g. RU486 and prednisolone) were added, at 5-min intervals.
The platelet aggregation response was recorded to plateau or for a maximum of 5 min. The degree of platelet aggregation with the vehicle was then compared with that measured after treatment and percentages of aggregation were calculated. In selected experiments, the TxA 2 receptor agonist U46619 (1 µM) or collagen (20 µg/ml) were used 19 .
HPLC determination of lipid release
Quantification of lipid release from resting and activated platelets was performed using a recently described chromatographic method 20 . Before HPLC analysis, lipid products were derivetised with ADAM reagent (1 µg/µl) before injection into an HPLC system consisting of a 4.6 x100 mm 3 µm ODS Spherisorb column (phase Sep, UK), a 2150 -pump (LKB, Bromma, Sweden), a FP-920 fluorescence detector (Jasco Tokyo, Japan), and a SCL-6B auto injector (Shimadzu, Kyoto, Japan). As mobile phase for the HPLC a mixture of acetonitrile and water (85/15 v:v) was used. Integration was performed with the Prime Software (HPLC Technology Ltd, Welwyn Garden, UK). Unknown samples were determined against standard curves prepared by spiking blank PPP with TxB 2 or AA, range from 6.25 to 125 ng/ml in both cases, or ranging from 5 to 40 ng/ml for 12-R-HETE and 12-S-HHTrE. 
Results
GR ligands and platelet activation
Addition of ADP to PRP provoked a marked aggregation of human platelets, as expected. Preincubation with 10 µM prednisolone, but not dexamethasone, significantly reduced the platelet response to ADP (Figure 1a ). This inhibitory effect was restricted to prednisolone and its nitric oxide-releasing derivative NCX-1015, as hydrocortisone and dexamethasone were inactive (all GR ligands tested at 10 µM; Figure 1b ). Prednisolone caused a concentration-dependent inhibition of ADP-induced platelet aggregation that was ~80% maximal at 3 µM; a 1 µM concentration was without effect (Figure 1c) . The GR antagonist RU486 (10 µM) was inactive by itself on the ADP response however it reversed prednisolone-mediated inhibition of platelet aggregation, implying that this was a receptor mediated event. The anti-aggregatory effect of prednisolone was also observed on U46619-induced platelet aggregation (Figure 1c) , although only at 10 µM concentration. Similar inhibition of collagen (20 µg/ml)-induced aggregation was seen: observing 20±2% and 65±4% inhibition for 3 µM and 10 µM prednisolone, respectively (data from three distinct donors).
The inhibitory effect of prednisolone on platelet function was not restricted to aggregation. Table 1 summarises HPLC analyses for lipid metabolites in ADP-stimulated platelets. At concentrations congruent with inhibition of aggregation, prednisolone inhibited TxB 2 and 12-SHHTrE, but not 12-R-HETE or AA, generation ( Table 1 ). The nitro-derivative NCX-1015, tested only at 10 µM, mimicked the effect of prednisolone, whereas dexamethasone was markedly less active. When tested at 3 µM, the latter glucocorticoid failed to affect the release (Table 1) . Aspirin was used as positive control in these experiments, and it inhibited TxB 2 and 12-S-HHTrE formation by ≥50%.
Detection of GR in human platelets
Immunochemical staining of washed platelets illustrated GR expression in permeabilised, but not non-permeabilised, platelets (Figure 2) . Incubation with an anti-P-selectin antibody produced positive staining of both preparations, whereas the anti-GR antibody was selective in its immunoreactivity only in permeabilised platelets. Dual colour imaging demonstrated the authenticity of the GR staining for platelets.
This crucial finding was confirmed by flow cytometric analysis, where human isolated platelets expressed GR at levels comparable to that of PBMC: in freshly isolated blood from 4 volunteers tested, platelet GR immuno-reactivity gave a value (median intensity fluorescence) of 163 ± 18
vs. values of 237 ± 45 in the PBMC population. Figure 3a illustrates data and confirms the dual staining with the anti-P-selectin antibody, as determined on permeabilised washed platelets. To further characterise platelet GR, Western blotting analysis was performed. These data demonstrate that platelet GR has an apparent molecular weight (~97 kDa) similar to that found for PBMC GR (Figure 3b ).
Biochemical characterization of GR in platelets
Scatchard plot analysis reported in Figure 4a clearly shows the negative hyperbole that was obtained suggesting two binding sites for dexamethasone; a high affinity site with an estimated 23.9 nM. This result was unexpected, and different from previous studies in PBMC, U937 cells and endothelial cells (to quote our own studies in which the identical protocol was applied) 21 . As MR was also found to be present in platelets, but not PBMC (see Figure 3b) , 
Platelet GR and accessory proteins
In the final part of the study we monitored the effect of prednisolone and dexamethasone on GR association with known chaperone proteins. Figure 7 shows that in resting platelets GR immunoprecipitated with the chaperone HSP70, HSP90 and the immunophillins FKBP51 and FKBP52. As internal controls we also ran comparative PBMC samples, in which GR is known to be associated with all these accessory proteins 24 .
The kinetics of this association was then analysed. Addition of dexamethasone or prednisolone to PRP provoked a time-dependent association of HSP90 ( Table 2 ) that was different from PBMC where this chaperone protein quickly dissociated from GR (see ref 21 and data not shown).
However, the two glucocorticoids displayed different effects on HSP70 (Figure 7a shows 
Discussion
In the present study we report the existence of a functional GR in human platelets and describe some of its behavioural and activation characteristics which differ from those reported in other cell types. This is potentially related to the existence of GR/MR heterodimers in platelets, and may explain the different effects produced by distinct GR ligands. It is proposed that the ability of prednisolone to down-regulate platelet activation here reported may have clinically important implications.
Platelets have long been recognised to have a pivotal role at the interface between coagulation and inflammation 25 predominantly because they could serve as stores for pro-inflammatory mediators that are rapidly released at sites of endothelial activation/injury 13, 26 . Classically, platelets have been considered unable to synthesise proteins and peptide mediators. For these reasons, we believe, the effects of glucocorticoids on platelets have been poorly investigated, since glucocorticoid-mediated GR activation has generally been linked to alterations of protein synthesis 8 . In addition, the few studies in which the effect of dexamethasone (often used as the 'gold standard' glucocorticoid) was tested, have found this glucocorticoid unable to alter platelet functions 4 . We provide here a novel biochemical mechanism that could be responsible for the paucity of data and contrasting findings reported in this field.
In contrast to the lack of effect of dexamethasone, addition of prednisolone to human PRP produced a concentration-dependent inhibition of second phase ADP-induced aggregation. This result was surprising, since glucocorticoids have been thought to be inactive on platelet 27 , an effect possibly linked to membrane stabilisation (often claimed for the neuroprotective actions of this group of drugs) 28 . In our experimental conditions, though, several other glucocorticoids (tested up to 10 µM) were unable to affect platelet aggregation. This suggested some selectivity in the actions of prednisolone, a finding corroborated by two other sets of data: the blockade of the effect by the GR antagonist RU486 28 , and the ability of a nitro-derivative of prednisolone 21 to inhibit platelet aggregation.
Pharmacological analysis of the actions of prednisolone revealed a distinct concentration dependent response against the aggregatory actions of ADP and U46619. This was supported by HPLC determination of different lipids generated from ADP-activated PRP and the contrasting behaviour displayed by prednisolone and dexamethasone on platelet aggregation was confirmed on other aspects of platelet biology. For instance, dexamethasone produced only minor alterations in lipid metabolism by activated platelets 20 . Comparative analyses of the data in Table 2 show that 1-10 µM prednisolone inhibited TxB 2 generation, whereas dexamethasone in the same concentration range was inactive. However both glucocorticoids inhibited 12-S-HHrTe and 12-R-HETE formation, with almost equal efficacy. Thus, the ability to suppress TxB 2 generation is one of the discriminatory roots of prednisolone efficacy on platelet aggregation.
This was achieved at clinically relevant concentrations, that are much lower than the mM concentrations used in the past to observe effect on platelet aggregation (e.g. see ref 27 ).
However, the efficacy of prednisolone on U46610-induced aggregation suggests interference with more than a single aspect of platelet biology that warrants further investigations. western blotting indicated that platelet GR was indistinguishable from PBMC GR in terms of molecular weight, however further investigations on the biochemical characteristics of platelet GR revealed other abnormalities compared to conventional GR biology.
GR functionality is tightly regulated by several receptor-associated proteins, of which several are heat shock proteins such as HSP90, HSP70 and the immunophilins FKBP51, FKBP52 and Cyp40 8, 24 . Although the number of receptor-associated proteins putatively associated with GR is ever increasing 29 , reconstitution experiments have shown that HSP90 and HSP70 are the major chaperones essential for unveiling the high affinity receptor-binding cleft with GR, with other associated proteins determining GR stability and nuclear translocation [30] [31] [32] . Thus, in PBMC and other nucleated cells, GR binding to its ligands (synthetic or natural glucocorticoids) causes HSP90 dissociation and exposure of the nuclear localization sequence 33 : the GR-ligand complex then dimerises and translocates into the nucleus, where it modulates the transcription of the genes containing the glucocorticoid response element (GRE) within their promoter region.
However, it is now clear that the GR-ligand complex can also affect gene expression indirectly by interfering with the function of cognate transcription factors 8 .
Experiments investigating GR binding in human platelets revealed several anomalies. For instance, Scatchard plot analysis indicated the existence at least two binding sites for dexamethasone, whereas only one was evident for aldosterone. The profile for the steroids differ from that observed in PBMC using the same whole-cell assay system as well as in U937 cells 21 , endothelial cells 34 and an osteoblast cell line (unpublished data). In line with this finding, 23 . In line with this hypothesis, GR and MR could be co-immunoprecipitated from human platelet, but not PBMC extracts. It is of interest that dexamethasone binding to human MR has also been reported in transfected systems 35, 36 . In addition, dexamethasone activates human MR to a significantly lower extent than GR, but, interestingly, with an affinity and potency very similar to aldosterone 35 . Thus, we wish to propose the hypothesis that addition of dexamethasone to platelets, by activating both GR and MR, produces a net null impact on activation. In contrast, the more selective GR ligand prednisolone inhibited the platelet response. In keeping with this hypothesis, platelet preincubation with aldosterone unmasked an anti-aggregatory effect of dexamethasone. Though the latter effect was relatively modest compared to the anti-aggregatory action of prednisolone, these results confirm the genuine inhibitory properties of platelet GR. More support for this conclusion may also be derived from experimental data obtained from a model of heart failure, in which an MR antagonist, eplerenone, prevented platelet activation 37 . A pro-inflammatory profile for chronic MR activation is now emerging which indicates a potential impact for this receptor on cardiovascular pathologies with an inflammatory etiology 38, 39 .
Finally, analysis of HSP association with GR again revealed a discrepancy from the classic mode of GR activation. Human platelets are known to contain HSP90 and HSP70 40, 41 . In the present study we could also detect FKBP51 and FKBP52 in a physical association with GR. However, the dynamic of heat shock protein interaction with GR was different from that reported for [30] [31] [32] , but rather the association increased in a timedependent fashion, with a calculated increment of >30% from 30 min onwards, perhaps suggesting that GR in the platelet is in an inactive or unfolded form and requires ligand to become functionally active and to re-associate with HSP. Interestingly, the ability to increase HSP90 association was shared by both dexamethasone and prednisolone, whereas the dynamics of HSP70 interaction with GR was markedly affected by prednisolone but not dexamethasone. In particular, prednisolone addition to platelets caused a transient association with GR (>50% increase at 30 min) followed by a rebound dissociation: this is opposite to that described in PBMC and U937 cells 21 . Thus, given the dichotomy of behaviour with respect to TxB 2 formation, it is tempting to propose that prednisolone's ability to alter HSP70 association with GR could be at the basis of its inhibition of ADP-induced platelet activation. In resting platelets, HSP70 is bound in a large complex together with HSP90 and protein phosphatase 1 42 . This present study suggests that GR is also part of this complex. Upon platelet activation, dephosphorylation of HSP70 is one of the first events to occur, causing the complex to disintegrate 42 . In is noteworthy that GR contains numerous potential phosphorylation sites 43 .
Evidence obtained during the past 10 years suggests that alteration in the GR phosphorylation status can affect GR-ligand binding, HSP90 interactions, receptor sub-cellular localization, nuclear-cytoplasmic shuttling, and transactivation potential 44 . The fact that we could not detect HSP90 dissociation is consistent with the hypothesis that platelet GR does not require nuclear translocation. Conversely, the ability of prednisolone to provoke HSP70 dissociation is in line with its profile of GR activation. Furthermore, it is highly likely that specific phosphorylation To conclude, we report the detection of GR in human platelets, thus increasing the list of nuclear receptors expressed in these cell fragments 41, 45 . As platelets have recently been shown to exhibit de novo protein synthesis 13 , it is possible that activation of these receptors might affect this specific response and consequent generation of pro-inflammatory cytokines and chemokines. In any event, platelet GR activation leads to a series of non-genomic responses, which require GR binding but are independent from activation of transcription/translation 7, 12 . The data we present not only uniquely demonstrate that glucocorticoids can rapidly (<1 h) alter platelet function, but also indicate that these responses are ligand-specific. Thus, at variance from the classical pharmacological classification of glucocorticoids, mechanistic differences amongst specific compounds are now emerging (e.g. see ref 46 from our group), and this is appears to be particularly evident in the case of platelet GR.
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